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Abstract
Background: The role of serum anti-Müllerian hormone (AMH) as predictor of in-vitro fertilization outcomes has
been much debated. The aim of the present study is to investigate the practicability of combining serum AMH
level with biological age as a simple screening method for counseling IVF candidates of advanced reproductive
age with potential poor outcomes prior to treatment initiation.
Methods: A total of 1,538 reference patients and 116 infertile patients aged greater than or equal to 40 years
enrolled in IVF/ICSI cycles were recruited in this retrospective analysis. A reference chart of the age-related
distribution of serum AMH level for Asian population was first created. IVF/ICSI patients aged greater than or equal
to 40 years were then divided into three groups according to the low, middle and high tertiles the serum AMH
tertiles derived from the reference population of matching age. The cycle outcomes were analyzed and compared
among each individual group.
Results: For reference subjects aged greater than or equal to 40 years, the serum AMH of the low, middle and high
tertiles were equal or lesser than 0.48, 0.49-1.22 and equal or greater than 1.23 ng/mL respectively. IVF/ICSI patients
aged greater than or equal to 40 years with AMH levels in the low tertile had the highest cycle cancellation rate
(47.6%) with zero clinical pregnancy. The nadir AMH level that has achieved live birth was 0.56 ng/mL, which was
equivalent to the 36.4th percentile of AMH level from the age-matched reference group. The optimum cut-off levels
of AMH for the prediction of nonpregnancy and cycle cancellation were 1.05 and 0.68 ng/mL, respectively.
Conclusions: Two criteria: (1) age greater than or equal to 40 years and (2) serum AMH level in the lowest tertile
(equal or lesser than 33.3rd percentile) of the matching age group, may be used as markers of futility for
counseling IVF/ICSI candidates.
Background
One of the most difficult aspects of assisted reproductive
treatment (ART) is to identify and counsel patients with
very low or virtually no chance of achieving live birth. A
report by the Ethics Committee of the American Society
of Reproductive Medicine (ASRM) nevertheless has pro-
vided a valuable guideline when considering fertility
treatment for patients with extremely poor prognosis.
According to the report, patients are defined as having
“poor prognosis” when the likelihood of a given ART
treatment achieving live birth is very low but not non-
existent (>1% and ≤ 5% per cycle); while those with
essentially no chance of achieving live birth with ART
treatment (≤ 1% per cycle) are considered as “futility” [1].
Prior to the advancements of ultrasound and immu-
noassay, the initial assessment of fecundity was largely
based on one’s chronological age. Although the age-
related decline in reproductive capacity has been well
documented in general population [2], the rate of ferti-
lity decline can vary considerably among individual
women of the same age [3,4], indicating that “ovarian
aging” may not be unequivocally dictated by chronologi-
cal aging. With the paradigms of modern ART emphati-
cally stressing the importance of treatment
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clearly in need.
Lacking a precise definition, the ovarian age is best
represented by ovarian reserve, the functional potential
of ovaries at any given time. Before initiating ART treat-
ment, ovarian reserve can be assessed ultrasonically by
antral follicle count (AFC), the ovarian volume and
ovarian blood flow, by endocrine markers such as basal
follicular stimulating hormone (FSH), inhibin-B, estra-
diol and anti-Müllerian hormone (AMH), and/or by
ovarian stimulatory tests such as the clomiphene citrate
challenge test (CCCT), the exogenous FSH ovarian
reserve test (EFORT) and the gonadotropin agonist sti-
mulation test (GAST) [3]. The ultimate goal of these
tests is to provide a more accurate prediction of the
potential success for patients prior to treatment initia-
tion, thus enabling a more feasible, patient oriented
treatment approach.
The aim of this study is therefore to assess the prac-
ticability of using serum AMH level, in conjunction with
chronological age, for screening and counseling
advanced-aged IVF candidates with high probability of
poor outcomes prior to treatment initiation. For the
present study, advanced age is defined as equal or above
forty years old, and poor outcomes are defined as IVF/
ICSI cycles resulting either in cancellation or
nonpregnancy.
Methods
Study subjects
Medical records were retrospectively examined for
patients who sought fertility consultation or treatment
at the Infertility Division of the Department of Obste-
trics-Gynecology, Mackay Memorial Hospital from
December 1st, 2006 to May 31st, 2010. The study proto-
col was approved by the Institutional Review Board of
Mackay Memorial Hospital in Taipei, Taiwan.
For the reference population, the inclusion criteria
were patients who fitted the medical definition of infer-
tility “one year of unprotected intercourse but not preg-
nant” and without any of the following exclusion
criteria: (1) menopause or premature ovarian failure sta-
tus (Day 3 serum FSH level > 10 IU/mL), (2) history of
ovarian or adnexal surgery, (3) suspicious findings of
ovarian malignancy, and (4) presence of endocrine dis-
orders such as diabetes mellitus, hyperprolactinemia,
thyroid dysfunction, congenital adrenal hyperplasia,
Cushing’s syndrome, adrenal insufficiency, and polycys-
tic ovary syndrome. In addition, severe underweight or
overweight patients were also excluded (BMI < 20 or >
27). For the analysis of IVF patients ≥ 40 years of age,
the inclusion criteria were the same as the ones for
reference population, with the addition of having under-
gone IVF during the same period of time.
Study design
The variation of AMH levels among different races and
ethnicities has been well documented in the study by
Seifer et al. [5]. Since the chart for age-related distribu-
tion of AMH levels has not been established for Asian
population, it was pertinent that an age-specific refer-
ence values must first be formulated. After applying the
above exclusion criteria, AMH data of 1,538 infertility
patients between the ages of 23 to 46 were obtained.
For each age group, the AMH levels were further strati-
fied into respective percentiles, serving as reference
values for the next phase of this study.
The relationship between age and serum AMH levels
on IVF/ICSI outcomes in infertility patients ≥ 40 years
of age was investigated in the following phase. Of all the
reference infertility patients ≥ 40 years of age (n = 378),
only the ones who had undergone IVF/ICSI were
enrolled (n = 116). These 116 subjects were further
divided into three groups according to the low, middle
and high tertiles (≤33.3
rd percentile, 33.4-66.6
th percen-
tile, and ≥ 66.7
th percentile) from the AMH reference
values for the 378 patients ≥ 40 years of age. The cycle
outcomes were then analyzed and compared among
each individual group.
The nadir serum AMH levels capable of achieving live
birth were identified and ranked according to the refer-
ence AMH values of corresponding reference age
groups. Correlations between AMH levels and outcomes
were also observed for the infertility patients aged 35 or
younger who underwent IVF/ICSI during the same per-
iod (n = 323). Lastly, the serum AMH cut-off values for
the prediction of nonpregnancy and cycle cancellation
for IVF/ICSI patients with aged 40 and above were
further quantified using the receiver operating charac-
teristic (ROC) curve analysis.
Ovarian stimulation protocols
All IVF/ICSI patients received either the GnRH agonist
long protocol or the GnRH antagonist protocol. All
patients received a starting dosage of 375 IU of recom-
binant follicle-stimulating hormone (r-FSH; Gonal-F;
Serono Laboratories, Aubonne, Switzerland) and 150 IU
of human menopausal gonadotropin (hMG; Menopur;
Ferring GmbH, Kiel, Germany) for three consecutive
days, and the dosage was then adjusted every two to
three days in accordance with the follicle growth until
the day of hCG administration. For the GnRH agonist
group, leuprolide acetate (Takeda Pharma GmbH, Stol-
berg, Germany) was given at a daily dose of 1 mg, start-
ing on the twenty-first day of the previous menstrual
cycle until the serum levels of estradiol fell below 30 pg/
mL, and patients then began daily gonadotropin injec-
tion. In the GnRH antagonist group, patients began
daily administration of r-FSH and hMG on the second
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follicle reached 14 mm in diameter, daily injection of
0.25 mg of cetrorelix (Cetrotide; Serono, Baxter Oncol-
ogy GmbH, Halle, Germany) was given until the day of
hCG administration.
When at least two follicles reached 18 mm in dia-
meter, 10,000 IU hCG (Pregnyl; Schering-Plough, Kenil-
worth, NJ, USA) was administered and oocyte retrieval
was performed 34-36 hours later. Conventional IVF or
ICSI was conducted 4-6 hours post oocyte retrieval. For
IVF, each oocyte was inseminated with 20 × 10
3 motile
spermatozoa in a single droplet containing 20 μl of ferti-
lization medium (Quinn’s Advantage Fertilization med-
ium; SAGE IVF Inc. Trumbull, Connecticut, U.S.A.). For
ICSI, 1-2 μl washed spermatozoa were placed in 7%
polyvinylpyrrolidone (PVP; SAGE IVF Inc.) and a sperm
was injected into each denuded oocyte using standar-
dized techniques. Each embryo was cultured in a single
droplet containing 20 μl of medium (Quinn’s Advantage
Cleavage medium; SAGE IVF Inc.) and incubated under
the atmospheric composition of 5% CO2,5 %O 2 and
90% N2 at 37°C. All embryo transfers were performed at
72 hours post oocyte retrieval.
Luteal support and confirmation of pregnancy
The luteal phase was supported by intramuscular injec-
tion of 50 mg of progesterone and vaginal supplementa-
tion of 300 mg micronized progesterone (Progeffik;
Effik, Paris, France) or Crinone 8% progesterone gel
(Columbia Laboratories, Inc., Livingston, NJ) once per
day. Serum hCG was measured 14 days after oocyte
retrieval and a value above 5 IU/ml was designated as
positive pregnancy. Clinical pregnancy was defined as a
pregnancy diagnosed by ultrasonographic visualization
of the gestational sac. Viable pregnancy was defined as
gestation age greater than 7
th weeks with documented
fetal cardiac activity by ultrasound.
Serum AMH measurement
AMH levels were measured by enzyme-linked immuno-
sorbent assay kit (ELISA, Diagnostic Systems Labora-
tories, Webster, TX). The detection range of the assay
was between 0.025-15 ng/mL with the detection limit
(0.017 ng/mL). Values below the detection limits were
considered as zero. The intra-and-interassay variation
coefficients were 4.6% and 8.0% respectively. Samples
from all subjects were obtained via venipuncture and
analyzed by the same laboratory (Department of Immu-
noassay, Mackay Memorial Hospital, Taipei, Taiwan).
The samples were processed according to the manufac-
turer instructions by centrifuging at 1400 × g for 10
minutes to separate cellular contents and the debris,
then the serum was transferred to sterile polypropylene
tubes to be preserved at -70°C until assayed.
Statistical analysis
Statistical analysis was performed using SigmaPlot
(Systat Software Inc., Chicago, IL, USA) and MedCalc
10.2 (MedCalc Software, Mariakerke, Belgium). Continu-
ous variables were presented as mean and standard
deviation (SD). For categorical variables, the values were
presented as raw frequencies with corresponding per-
centages, and the between-group differences were
assessed either by Chi square test with Yates correction
if needed, or by Fisher exact test. The 95% confidence
interval of the binomial distribution for clinical pregnan-
cies in each of the three groups were calculated by the
modified Wald method. Receiver operating characteristic
(ROC) curves were generated to investigate the predict-
ability of AMH levels in IVF cycle cancellation and non-
pregnancy. The sensitivity,s p e c i f i c i t y ,p o s i t i v ea n d
negative predictive values were calculated for the opti-
mal AMH cut-off levels determined by ROC curve ana-
lysis. The results were considered statistically significant
at p < 0.05.
Results
Both the mean and median AMH values of the refer-
ence group showed a progressive decline with advancing
age (Table 1). The low, middle, and high tertiles of
serum AMH for reference subjects with aged 40 years
and above were ≤0.48, 0.49-1.22 and ≥1.23 ng/mL
respectively. The mean age differences among the three
groups analyzed by ANOVA were found to be statisti-
cally insignificant. The sample size was considered suffi-
cient by one tailed post hoc power analysis (a =0 . 0 5
and a power of 80%).
The IVF/ICSI outcomes for subjects of age ≥ 40
years are presented in Table 2. After dividing them
according to the low, middle and high tertiles from
the AMH reference values for patients with age ≥ 40
years, a trend of negative cycle outcomes was
observed toward the lower end of AMH tertile. Sub-
jects with AMH concentrations in the low tertile had
zero clinical pregnancy, which differed significantly
from those of the middle (23.7%, p < 0.02) and the
high tertiles (29.8%, p < 0.0001). On the other hand,
women with AMH concentrations in the low tertile
had the highest rate of cycle cancellation (47.6%),
which also differed significantly from those of the
middle (15.7%, p < 0.04) and the high tertiles (1.7%, p
< 0.01). When comparing the outcomes between the
higher two tertiles, a significant difference was noted
only for cycle cancellation (15.7% vs. 1.7%, p = 0.02)
but not for clinical pregnancy rate (23.7% vs. 29.8%, p
> 0.05). The 95% confidence interval of the binomial
distribution for clinical pregnancies from the low to
high tertile was zero to 16 percent, 13-39 percent and
19-42 percent respectively.
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in the group aged ≥ 40 years was 0.56 ng/mL, which
was equivalent to the 36.4
th percentile of AMH level
from the reference group of the same age. For the
group aged ≤35 years, live birth was achievable even
for subjects with diminished ovarian reserve. The nadir
AMH level that achieved live birth in that group was
0.26 ng/mL, which was equivalent to the 1.7
th
percentile of AMH level from the reference group of
t h es a m ea g e .
With respect to the prediction of cycle cancellation
and nonpregnancy for infertility patients aged ≥ 40
years, AMH demonstrated a high discriminative ability
with respective areas under curve (AUC) of 0.77 and
0.66 by ROC curve analysis. The optimal cut-off level of
AMH for the prediction of IVF cycle cancellation was
Table 1 The age-related distribution chart of serum AMH level (ng/mL) for reference infertility patients
Age Mean ± SD 5
th centile 10
th centile 25
th centile Median 75
th centile 90
th centile 95
th centile n
≤ 4.07 ± 1.98 1.74 1.88 2.61 3.38 5.46 7.12 8.57 36
27 3.82 ± 1.93 0.30 1.39 2.45 3.43 5.17 6.42 7.60 30
28 4.41 ± 2.01 0.77 1.80 2.78 4.47 5.75 7.33 7.70 45
29 3.79 ± 1.09 1.08 1.41 2.27 3.48 5.31 6.74 7.16 70
30 3.77 ± 1.96 1.03 1.15 2.26 3.38 5.52 6.57 6.90 82
31 3.61 ± 2.14 0.83 1.23 1.81 3.20 4.84 6.85 7.68 104
32 3.80 ± 2.08 0.68 1.11 2.23 3.62 5.21 6.97 7.68 127
33 3.29 ± 1.90 0.88 1.09 1.66 2.91 4.63 5.97 6.80 129
34 2.81 ± 1.99 0.53 0.75 1.24 2.35 3.78 6.01 7.18 149
35 3.15 ± 1.89 0.67 0.83 1.70 2.83 4.51 5.79 6.57 104
36 3.08 ± 1.83 0.81 1.06 1.33 2.77 4.38 5.40 6.57 86
37 2.61 ± 1.65 0.75 0.78 1.12 2.47 3.49 5.12 5.67 69
38 2.03 ± 1.40 0.06 0.19 0.88 1.91 2.94 3.87 4.64 73
39 1.45 ± 1.35 0.05 0.11 0.48 1.07 2.02 3.14 4.65 56
40 1.68 ± 1.36 0.11 0.13 0.63 1.42 2.41 3.65 4.20 126
41 1.18 ± 1.32 0.02 0.05 0.29 0.86 1.35 3.04 3.48 88
42 0.91 ± 0.97 0.01 0.05 0.23 0.60 1.24 2.34 3.53 47
43 0.79 ± 0.77 0.00 0.05 0.06 0.63 1.50 2.09 2.48 43
44 0.69 ± 0.61 0.06 0.08 0.28 0.52 0.98 1.36 2.36 32
45 0.66 ± 0.66 0.13 0.14 0.32 0.54 0.67 1.12 2.73 26
46 0.50 ± 0.40 0.00 0.00 0.10 0.52 0.81 1.11 1.14 16
All 2.71 ± 2.04 0.14 0.40 0.65 2.36 3.09 5.78 6.82 1538
≥ 40 1.17 ± 1.99 0.05 0.06 0.32 0.78 1.56 2.91 3.53 378
Table 2 Outcomes of IVF/ICSI cycles in women of advanced reproductive age (≥ 40 years old)
Serum AMH tertiles (ng/mL)
Total subjects Low
(≤ 0.48)
Middle
(0.49~1.22)
High
(≥ 1.23)
Total cycle 116 21 38 57
Cancelled cycle (%) 17 (14.7) 10 (47.6)
§ 6 (15.7)* 1 (1.7)
Mean age 41.5 ± 1.4 42.8 ± 2.3 41.1 ± 1.3 41.3 ± 1.4
Peak E2 level (pg/mL) 1542.1 ± 1146.5 802.6 ± 748.9 1050 ± 699 2095.8 ± 1156.2
Number of oocytes retrieved 6.1 ± 4.6 2.4 ± 2.9 4.7 ± 2.5 8.1 ± 5.1
Number of mature oocytes 4.7 ± 3.7 1.5 ± 1.73 3.9 ± 2.5 6.3 ± 3.9
Embryos obtained 3.8 ± 2.9 1.8 ± 2.4 3.1 ± 2.2 4.8 ± 3.1
Embryos transferred 2.8 ± 1.2 1.6 ± 1.3 2.6 ± 1.0 3.2 ± 1.0
Clinical pregnancy per cycle (%) 26 (22.4) 0 (0)
§ 9 (23.7) 17 (29.8)
Abortion per cycle (%) 7 (26.9) 0 (0) 0 (0) 7 (41.2)
Viable pregnancy per cycle (%) [FHB (+) & > 7 wks.] 19 (16.4) 0 (0)﹟ 9 (23.7) 10 (17.5)
§ p < 0.05 compared with the middle tertile and the high tertile
*p < 0.05 compared with the high tertile
﹟p < 0.05 compared with the middle tertile
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negative predictive value of 92.0%. The optimal cut-off
level of AMH for the prediction of IVF nonpregnancy
was 1.05 ng/mL (p < 0.05), with specificity of 86.7% and
positive predictive value of 91.4%. The cut-off levels of
AMH for IVF cycle cancellation (0.68 ng/mL) and non-
pregnancy (1.05 ng/mL) corresponded to the 43.8
th and
56.8
th percentile of the reference serum AMH level
from the matching age group respectively. The complete
sensitivity, specificity, positive and negative predictive
values are summarized in Table 3.
Discussion
The most pertinent concern to the infertile couple has
always been the success rate of specific ART treatments.
Therefore, numerous studies have been dedicated to
identify reliable markers that may help in predicting
outcomes in IVF cycles, as well as the feasibility of
applying these markers in patient counseling prior to
treatment initiation. A recent meta-analysis has con-
cluded that female age, duration of subfertility, basal
FSH level and number of retrieved oocytes are all pre-
dictors of pregnancy in IVF cycles [6]. However, many
other potential markers, including serum AMH level,
were not incorporated as the factors analyzed in that
study.
Since its discovery, AMH has been a promising mar-
ker in various clinical setting of ART. Initially viewed as
an accurate marker of ovarian reserve [7,8], AMH was
subsequently found to be a reliable predictor of con-
trolled ovarian hyperstimulation for both poor [9,10]
and hyper responses [11,12]. In addition, one study
reported AMH to be a competent surrogate marker for
antral follicle count in the diagnosis of PCOS by the
Rotterdam Criteria [13]. Nevertheless, the relationship
between serum AMH level and IVF pregnancy outcome
still has not been fully elucidated. A recent review by
Broekmans et al. has concluded that ovarian reserve
tests, including AMH, were not good predictors of preg-
nancy in IVF cycles [14].
There are several possible rationales for the poor per-
formance of AMH in predicting pregnancy in IVF
cycles. First of all, the international assay standard for
AMH measurement is lacking. Up to dates, only few
studies have attempted to create age-specific serum
AMH values for the infertile population [15] and healthy
c o h o r t s[ 1 6 , 1 7 ] .S e c o n d l y ,w h i l et h e s es t u d i e sh a v ea l l
observed a similar trend of steady decrement of AMH
level with advanced age, a wide range of distribution of
AMH levels among each age group was also noted
[15-17]. The wide variability was also observed in the
AMH data from our reference group study, and that
was one of the primary reasons that median was used
for analysis instead of arithmetic mean. Furthermore,
among most studies that investigated the predictability
of AMH levels in IVF pregnancy, no specific age group
was targeted for the enrolled subjects. Therefore, a wide
range of cut-off values was presented (0.10-2.70 ng/mL)
[7,18-25] with various sensitivity, specificity, positive and
negative predictive values. In short, serum AMH value
alone may not be a sufficient predictor of pregnancy in
IVF cycles without other considering factors.
Furthermore, the quality and quantity of oocytes are
both important determinants for the success in ART.
Several studies have demonstrated that serum AMH
may also possess the additional ability to predict the
quality of oocytes and embryos [18,26-28], while others
have failed to replicate such relationship [21,29,30]. In a
well-designed study by Wang et al., the authors revealed
that both the clinical pregnancy rate per retrieval and
live birth rate per embryo transfer did not differ signifi-
cantly across all three AMH tertiles (≤0.29, 0.30-1.20
and ≥1.21 ng/ml) for women aged <34 years. This indi-
cated that favorable outcomes may still be attained for
the infertile patients of younger age on the basis of bio-
logically competent oocytes, despite of the diminished
ovarian reserve [31]. The observation drawn from the
present study also demonstrated that pregnancy was still
achievable even in patients younger than 35 years old
with extremely low AMH level (0.26 ng/mL; 1.7
th per-
centile). These findings concurred with the conclusions
drawn from the recent meta-analysis by van Loender-
sloot et al., which found that female age, hence oocyte
quality, was the most important predictor of pregnancy
in IVF cycles among almost all of the analyzed studies
[6].
On the other hand, the present study disclosed that
for women of advanced reproductive age (≥ 40), having
AMH concentrations in the higher two tertiles was asso-
ciated with nonsignificant difference in clinical preg-
nancy rate, which differed significantly from those with
AMH level in the lowest tertile. In addition, no live
birth was achieved for women with AMH in the lowest
tertile with extremely high cycle cancellation rate. These
Table 3 Prediction of cycle cancellation and nonpregnancy by serum AMH levels in women of advanced reproductive
age (≥ 40 years old)
Cut-off AMH level (ng/mL) ROCAUC Sensitivity (%) Specificity (%) PPV (%) NPV (%) Significance level
Cycle cancellation 0.68 0.77 64.7 85.1 47.8 92.0 p = 0.0001
Nonpregnancy 1.05 0.65 42.7 86.9 91.4 31.7 p = 0.022
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with AMH level in the lowest tertile, poor IVF/ICSI
cycle outcomes could be expected due to poor oocyte
quantity as well as quality. Though the range of AMH
tertiles were defined differently, similar observation was
also made in the study by Wang et al for women of
advanced reproductive age [31].
One of the limitations of the present study was the
relative small sample size (n = 116) in the IVF group ≥
40 years old. Being a retrospective study which targeted
only on a specific group of infertile population, a larger
sample size is indeed needed in the future to confirm
the results of this study. Furthermore, the results from
the present study were to simply present an easier and
more reliable counseling tool for evaluating and identify-
ing patients of potential poor outcome, rather than a
tool of exclusion. The patients should always have final
decision of whether or not to receive treatment.
Conclusions
To the best of our knowledge, this is the first ever study
that investigated the lower limits of serum AMH level
capable of achieving viable pregnancy in advanced-aged
IVF/ICSI patients, specifically those equal and over forty
years old. In addition, from our data, we were able to
derive the serum AMH cut-off values that may reliably
predict the likelihood of cycle cancellation as well as
nonpregnancy for IVF/ICSI patients equal and over
forty years old. To sum up, we propose two simple cri-
teria for patient counseling: (1) age equal and over forty
years and (2) serum AMH level in the low tertile
(≤33.3
rd percentile) of the matching age group, as the
markers of futility for IVF/ICSI due to high cancellation
rate and slim chance for clinical pregnancy.
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